FREMONT, Calif., Aug. 23, 2017 (STL.NEWS) Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that Washington University School of Medicine in St. Louis, MO, has been added as a clinical site in the companys ongoing SCiStar Phase 1/2a clinical trial of AST-OPC1, a stem-cell derived investigational therapy, in patients with severe cervical spinal cord injury (SCI). There are now nine clinical sites enrolling patients in the study.
Washington University and its partner Barnes-Jewish Hospital have one of the largest clinical spine care practices in the United States. W. Zachary Ray, MD, Associate Professor of Neurological and Orthopedic Surgery at Washington University School of Medicine, will be the sites principal investigator. Patients enrolled in the trial will receive the AST-OPC1 treatment during surgery at Barnes-Jewish.
Given the studys encouraging early results, we look forward to evaluating whether AST-OPC1 can advance treatment options for patients with severe cervical spinal cord injuries. This investigational therapy is an important contribution to our comprehensive program to treat spinal cord injuries here at Washington University and Barnes-Jewish, said Dr. Ray.
Barnes-Jewish Hospitals Trauma Center was the first in Missouri to receive the American College of Surgeons (ACS) Level I verification, which is the highest national recognition possible from ACS.
Washington University School of Medicine is a great addition to our current AST-OPC1 SCiStar study. We hope Washington University School of Medicine will also participate in a future randomized controlled trial of AST-OPC1, stated Dr. Edward Wirth III, Chief Medical Officer of Asterias Biotherapeutics.
About the SCiStar Trial
The SCiStar trial is an open-label, single-arm trial testing three sequential escalating doses of AST-OPC1 administered at up to 20 million AST-OPC1 cells in as many as 35 patients with subacute motor complete (AIS-A or AIS-B) cervical (C-4 to C-7) SCI. These individuals have essentially lost all movement below their injury site and experience severe paralysis of the upper and lower limbs. AIS-A patients have lost all motor and sensory function below their injury site, while AIS-B patients have lost all motor function but may have retained some minimal sensory function below their injury site. AST-OPC1 is being administered 21 to 42 days post-injury. Patients will be followed by neurological exams and imaging procedures to assess the safety and activity of the product.
The study is being conducted at nine centers in the U.S. Clinical sites involved in the study include the Medical College of Wisconsin in Milwaukee, Shepherd Medical Center in Atlanta, University of Southern California (USC) jointly with Rancho Los Amigos National Rehabilitation Center in Los Angeles, Indiana University, Rush University Medical Center in Chicago, Santa Clara Valley Medical Center in San Jose jointly with Stanford University, Thomas Jefferson University Hospital in partnership with Magee Rehabilitation Hospital in Philadelphia, UC San Diego Health in San Diego, California, and Washington University School of Medicine in partnership with Barnes-Jewish Hospital in St. Louis, MO.
Asterias has received a Strategic Partnerships Award grant from the California Institute for Regenerative Medicine, which provides $14.3 million of non-dilutive funding for the Phase 1/2a clinical trial and other product development activities for AST-OPC1.
Additional information on the Phase 1/2a trial, including trial sites, can be found at http://www.clinicaltrials.gov, using Identifier NCT02302157, and at the SCiStar Study Website (www.SCiStar-study.com).
About AST-OPC1
AST-OPC1, an oligodendrocyte progenitor population derived from human embryonic stem cells originally isolated in 1998, has been shown in animals and in vitro to have three potentially reparative functions that address the complex pathologies observed at the injury site of a spinal cord injury. These activities of AST-OPC1 include production of neurotrophic factors, stimulation of vascularization, and induction of remyelination of denuded axons, all of which are critical for survival, regrowth and conduction of nerve impulses through axons at the injury site. In preclinical animal testing, AST-OPC1 administration led to remyelination of axons, improved hindlimb and forelimb locomotor function, dramatic reductions in injury-related cavitation and significant preservation of myelinated axons traversing the injury site.
In a previous Phase 1 clinical trial, five patients with neurologically complete, thoracic spinal cord injury were administered two million AST-OPC1 cells at the spinal cord injury site 7-14 days post-injury. Based on the results of this study, Asterias received clearance from FDA to progress testing of AST-OPC1 to patients with cervical spine injuries in the current SCiStar study, which represents the first targeted population for registration trials. Asterias has completed enrollment in the first four cohorts of this study. Results to date have continued to support the safety of AST-OPC1. Additionally, Asterias has recently reported results suggesting reduced cavitation and improved motor function in patients administered AST-OPC1 in the SCiStar trial.
About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc. is a biotechnology company pioneering the field of regenerative medicine. The companys proprietary cell therapy programs are based on its pluripotent stem cell and immunotherapy platform technologies. Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of neurology and oncology. AST-OPC1 (oligodendrocyte progenitor cells) is currently in a Phase 1/2a dose escalation clinical trial in spinal cord injury. AST-VAC1 (antigen-presenting autologous dendritic cells) is undergoing continuing development by Asterias based on promising efficacy and safety data from a Phase 2 study in Acute Myeloid Leukemia (AML), with current efforts focused on streamlining and modernizing the manufacturing process. AST-VAC2 (antigen-presenting allogeneic dendritic cells) represents a second generation, allogeneic cancer immunotherapy. The companys research partner, Cancer Research UK, plans to begin a Phase 1/2a clinical trial of AST-VAC2 in non-small cell lung cancer in 2017. Additional information about Asterias can be found at http://www.asteriasbiotherapeutics.com.
FORWARD-LOOKING STATEMENTS
Statements pertaining to future financial and/or operating and/or clinical research results, future growth in research, technology, clinical development, and potential opportunities for Asterias, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of Asterias, particularly those mentioned in the cautionary statements found in Asterias filings with the Securities and Exchange Commission. Asterias disclaims any intent or obligation to update these forward-looking statements.
source; Asterias Biotherapeutics , published on STL.NEWS by St Louis Media, LLC
See more here:
Washington University School of Medicine; Asterias Biotherapeutics ... - STL.News
- Diversifying marrow registry critical to achieve medical equity say advocates - WISH TV Indianapolis, IN - September 16th, 2022
- COVID-19 vaccine is a gift that is saving lives - CatholicPhilly.com - December 24th, 2021
- Biology for Kids: The Movement of Substances in and out of ... - December 10th, 2021
- Stem cell laws and policy in the United States - Wikipedia - December 10th, 2021
- IU School of Medicine researchers discover new potential for functional recovery after spinal cord injury - Spinal News International - July 21st, 2021
- Stem Cell Treatment Centers - Indiana Stem Cell | Call Today - June 23rd, 2021
- Stem Cell Therapy | Indiana Medical Center - June 23rd, 2021
- The unsexy side of Covid-19 vaccines gets Wall Streets attention - Deccan Herald - December 17th, 2020
- Blocking energy pathway reduces GVHD while retaining anti-cancer effects of T-cells - Science Codex - November 10th, 2020
- Notre Dame Adjusts to the COVID-19 Pandemic | Notre Dame Magazine | University of Notre Dame - ND Newswire - July 7th, 2020
- Head of FDA urged to ensure any COVID vaccine be free of abortion connection - My catholic standard - April 23rd, 2020
- What Explains The COVID-19 Race Gap? : Shots - Health News - NPR - April 23rd, 2020
- If Social Distancing Is Impossible in Prisons, People Should Be Freed - Truthout - March 20th, 2020
- Blood drive to honor Franklin child with cancer - Daily Journal - January 27th, 2020
- Spinal Stenosis and Stem Cell Therapy ... - Indiana Polyclinic - January 9th, 2020
- Innovative Cellular Therapeutics Appoints Cell and Gene Therapy Manufacturing Expert Christopher Ballas, Ph.D., as SVP of Manufacturing - BioSpace - January 9th, 2020
- Robots help them 'find their passion' - News Dispatch - January 9th, 2020
- Seeking the Killer Space App with Space Tango - The Planetary Society - December 3rd, 2019
- 15 Antiviral Herbs to Keep You Healthy - Healthline - October 21st, 2019
- Juul Temporarily Halts Online Sales Of Flavored E-Cigarettes, But Critics Say That's Far From Enough - Kaiser Health News - October 21st, 2019
- When You Need Stem Cells, You May Appreciate the Donor Registry - 93.1 WIBC Indianapolis - September 22nd, 2019
- Research suggests new approach for treating inflammation - ScienceBlog.com - September 22nd, 2019
- Reviewing Assembly Biosciences Inc. (ASMB)'s and Neuralstem Inc. (NASDAQ:CUR)'s results - CryptoCoinsTribune - September 22nd, 2019
- A New Vaccine Could Mean the End of Polio - The National Interest Online - September 22nd, 2019
- Bone Marrow & Blood Stem Cell Transplant | IU Health - May 5th, 2019
- Stem Cell Research Facilities - Indiana Stem Cell - May 1st, 2019
- Stem Cell Therapy and Irritable Bowel Syndrome - Indiana ... - April 5th, 2019
- Learn more about Stem Cell Therapy in Fort Wayne Indiana ... - October 6th, 2018
- Stem Cell Treatment Program - Indiana Polyclinic - July 3rd, 2018
- Stem Cell Treatment Center | IN - July 3rd, 2018
- Regenerative Cell Therapy in Fort Wayne, Indiana - June 22nd, 2018
- IUPUI researchers finding collaboration, breakthroughs in lab facility - IU Newsroom - September 6th, 2017
- South Bend man a 'walking miracle' after cancer treatment ... - South Bend Tribune - September 4th, 2017
- Somatic SNAFUCan a Few Mutant Microglia Cause Neurodegenerative Disease? - Alzforum - September 4th, 2017
- FDA Cracks Down On Stem-Cell Clinics Selling Unapproved Treatments - Northeast Indiana Public Radio - September 4th, 2017
- News | Misericordia University: Alumnus tells first-year students they ... - Misericordia University - August 25th, 2017
- Asterias Enrolls First Patient in Final Cohort of SCiStar Clinical Trial - GlobeNewswire (press release) - August 9th, 2017
- Dance event aims to raise funds for cancer research - Daily Journal - August 7th, 2017
- Asterias Biotherapeutics Opens Two Additional Clinical Sites for ... - GlobeNewswire (press release) - August 7th, 2017
- Want more stem cells and a higher pain tolerance? Try ... - July 30th, 2017
- Chris Rickert: Science skeptics shouldn't steer UW hiring - Madison.com - July 4th, 2017
- The Benefits of Stem Cell Science to Your Health - November 25th, 2016
- Guidelines for Preventing Opportunistic Infections Among ... - September 5th, 2016
- Hematopoietic stem/progenitor cells, generation of induced ... - July 29th, 2016
- Indiana (Stem Cell) - what-when-how - July 25th, 2016
- Stem Cells and Development - Mary Ann Liebert, Inc. - October 19th, 2015
- StemEnhance Increase Adult Stem Cells from Bone Mirrow - October 19th, 2015
- Ethics of Stem Cell Research (Stanford Encyclopedia of ... - October 6th, 2015
- Faculty Positions in Stem Cell Biology, Employment | ASCB - September 30th, 2015
- Stem Cell Discoveries - About.com Education - September 19th, 2015
- Munster veterinary clinic offers stem cell therapy - July 2nd, 2015
- IUPUI biologist receives NIH grant to study how glaucoma develops in stem cells - March 10th, 2015
- Significant Findings in U.S. National Institutes of Health's Trial of Pluristem's PLX-R18 Cells for Treatment of Acute ... - February 19th, 2015
- IU researchers create the inner ear from stem cells ... - February 10th, 2015
- What's the role of virtues in the lab? - February 3rd, 2015
- Stem Cell News | Stem Cell Treatment, Stem Cell Research ... - December 24th, 2014
- Dr. Nia Smyrniotis at The Miami Stem Cell Treatment Center - December 24th, 2014
- Key mechanism, potential target to prevent leukemia found - November 14th, 2014
- IUPUI Stem Cell Research Could Expand Clinical Use of ... - October 15th, 2014
- Researchers Develop New Cells Meant to Form Blood Vessels, Treat Peripheral Artery Disease - October 14th, 2014
- Bone Marrow and Stem Cell Transplant Treatment | Simon ... - September 1st, 2014
- Spinal Stem Cell Treatment IN | Spinal Pain Treatment IN ... - August 26th, 2014
- Indiana University (Stem Cell) - what-when-how - August 24th, 2014
- Indiana Stem Cell Treatment Center - August 22nd, 2014
- Spinal Disc Treatment IN | Disc Pain Treatment IN | Dr ... - August 22nd, 2014